Tenaya Therapeutics Inc (NASDAQ: TNYA) kicked off on Monday, up 0.28% from the previous trading day, before settling in for the closing price of $3.57. Over the past 52 weeks, TNYA has traded in a range of $1.61-$7.01.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
While this was happening, its average annual earnings per share was recorded 19.57%. With a float of $65.58 million, this company’s outstanding shares have now reached $79.22 million.
Let’s determine the extent of company efficiency that accounts for 140 employees. In terms of profitability, gross margin is 58.87%, operating margin of -694.87%, and the pretax margin is -663.65%.
Tenaya Therapeutics Inc (TNYA) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Tenaya Therapeutics Inc is 17.22%, while institutional ownership is 57.28%. The most recent insider transaction that took place on Nov 18 ’24, was worth 4,787. In this transaction SVP, Accounting and Fin. Ops. of this company sold 2,258 shares at a rate of $2.12, taking the stock ownership to the 60,983 shares. Before that another transaction happened on Aug 16 ’24, when Company’s SVP, Accounting and Fin. Ops. sold 2,363 for $2.89, making the entire transaction worth $6,840. This insider now owns 63,241 shares in total.
Tenaya Therapeutics Inc (TNYA) Recent Fiscal highlights
In the latest quarterly report, which was put into the public domain on 9/30/2024, the organization reported -0.4 earnings per share (EPS), higher than consensus estimate (set at -0.44) by 0.04. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.33 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 19.57% per share during the next fiscal year.
Tenaya Therapeutics Inc (NASDAQ: TNYA) Trading Performance Indicators
Take a look at Tenaya Therapeutics Inc’s (TNYA) current performance indicators. Last quarter, stock had a quick ratio of 5.27.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.48, a number that is poised to hit -0.31 in the next quarter and is forecasted to reach -1.25 in one year’s time.
Technical Analysis of Tenaya Therapeutics Inc (TNYA)
Looking closely at Tenaya Therapeutics Inc (NASDAQ: TNYA), its last 5-days average volume was 7.09 million, which is a jump from its year-to-date volume of 1.05 million. As of the previous 9 days, the stock’s Stochastic %D was 86.38%. Additionally, its Average True Range was 0.39.
During the past 100 days, Tenaya Therapeutics Inc’s (TNYA) raw stochastic average was set at 80.41%, which indicates a significant decrease from 90.76% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 138.17% in the past 14 days, which was higher than the 106.20% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.14, while its 200-day Moving Average is $3.48. However, in the short run, Tenaya Therapeutics Inc’s stock first resistance to watch stands at $3.75. Second resistance stands at $3.93. The third major resistance level sits at $4.10. If the price goes on to break the first support level at $3.40, it is likely to go to the next support level at $3.23. Now, if the price goes above the second support level, the third support stands at $3.05.
Tenaya Therapeutics Inc (NASDAQ: TNYA) Key Stats
The company with the Market Capitalisation of 283.61 million has total of 79,221K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -124,080 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -25,630 K.
